Immune prognostic implications of PSMD14 and its associated genes signatures in hepatocellular carcinoma

PSMD14 played a vital role in initiation and progression of hepatocellular carcinoma(HCC).However,PSMD14 and its-related genes for the immune prognostic implications of HCC patients have rarely been analyzed.Messenger RNA expression profiles and clinicopathological data were downloaded from The Cancer Genome Atlas(TCGA)and International Cancer Genome Consortium(ICGC)database-Liver Hepatocellular Carcinoma(LIHC).Additionally,we used multi-dimensional bioinformatics analysis to construct and validate a PSMD14-based immune prognostic signature(including RBM45,PSMD1,OLA1,CCT6A,LCAT and IVD)for HCC prognosis prediction.Patients in the high-risk group shown significantly poorer survival than patients in the low-risk group.Calibration curves confirmed the good consistency between the clinical nomogram prediction and the actual observation.Gene set enrichment analyses(GSEA)revealed several significantly enriched pathways,which might help explain the underlying mechanisms.Besides,the rt-PCR further validates the expression of seven immune genes in HCC cells.Our study identified a novel PSMD14-based signature for HCC prognosis prediction,it provided new potential prognostic biomarkers and therapeutic targets for immunotherapy of HCC.

去泛素化酶PSMD14在肿瘤中的研究进展

泛素蛋白酶体系统(ubiquitin proteasome system,UPS)能够介导真核细胞中80%以上蛋白质的降解,对底物的蛋白稳定和功能发挥起到关键作用。作为一种重要的泛素化修饰调控因子,去泛素化酶能够从底物上切割泛素,修饰泛素链并加工泛素前体,与多种生理病理过程密切相关。其中,去泛素化酶PSMD14(proteasome 26S subunit,non-ATPase 14)位于蛋白酶体26S亚基,是一种非ATP酶组分。近年来,其在肿瘤发生发展中的作用越来越受到关注。本文将对PSMD14的结构、作用机制及其抑制剂在肿瘤中的研究进展进行综述。